Linical and Accelovance have merged to create a market-leading, midsized, global contract research organization (CRO) with a significant footprint across North America, Europe and Asia-Pacific. As the next step in the merger, Accelovance has incorporated Linical into its name and will operate as Linical Accelovance Group, which includes Linical Accelovance Americas, Europe, Romania and China. Linical is the ideal partner for drug developers looking to expand their program into new markets. Linical offers a personalized, hands-on service approach across a variety of therapeutic areas and in all phases of development. Linical Accelovance is an award winning, clinical development Contract Research Organization (CRO) focused on vaccine, oncology, dermatology, nutrition and women’s health (Phase I-IV programs). Providing global full CRO services to pharmaceutical companies, biotechs, CROs, and academic institutions; Linical Accelovance supports client needs by leveraging operational knowledge and patient recruitment strategies that result in successful clinical trials. Linical Accelovance owns and operates a Clinical Call Center that assists in recruitment, retention, and surveillance. This knowledge, applied externally to sites and coupled with the therapeutic talent and experience of our team members, creates predictable, controlled enrollment and retention of quality patients ensuring study success. Linical Accelovance has been nominated for the Vaccine Industry Excellence’s (ViE) Best CRO Award 11 consecutive years and been awarded the title in 2009, 2010, and 2011; and received a “Highly Recommended” distinction in 2013. This external validation of Linical Accelovance’s vaccine research experience and success is a result of our ability to guarantee budgets, control timelines, and accelerate patient enrollment – delivering business solutions that address our clients’ clinical needs. Established in 2005 with a corporate goal to deliver a personalized, hands-on service approach across a variety of therapeutic areas and in all phases of development, Linical Accelovance has made significant strides in the industry by combining strong business and operational perspective with clinical and medical expertise.
Phone: 561.421.1443
E-mail: information@linical.accelovance.com
Web: https://www.accelovance.com
Add：789 SW Federal Highway, Suite 100 ,Stuart, FL 34994
想要下载更多资料，请您添加微信了解详情！
微信号：csco2022
公众号：康安医药咨询
